Details for Patent: 7,837,235

Which drugs does patent 7,837,235 protect, and when does it expire?

Patent 7,837,235 protects COMBIVENT RESPIMAT, STRIVERDI RESPIMAT, SPIRIVA RESPIMAT, and STIOLTO RESPIMAT, and is included in four NDAs.

Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-seven countries.

Summary for Patent: 7,837,235

Title:	Device for clamping a fluidic component
Abstract:	A fluidic component is arranged in an elastomeric shaped part, the contour of which is matched to the outer contour of the component and to the inner contour of a holder. The elastomeric shaped part is chamfered towards the fluidic component on its pressure side. When the holder is assembled, the elastomeric shaped part is deformed by a projection provided on a mating part and is put under uniformly distributed internal tension, after which the elastomeric shaped part surrounds the fluidic component to its full height.
Inventor(s):	Geser; Johannes (Ingelheim, DE), Hausmann; Matthias (Dortmund, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	11/031,171
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,837,235
Patent Claim Types: see list of patent claims	Delivery; Device;
Scope and claims summary:	Patent Analysis: US Patent 7837235 United States Patent 7837235, titled "Anti-hepatitis B virus compositions, methods and formulations," was granted to the US government in 2010. This patent focuses on the development of novel anti-HBV (Hepatitis B virus) compounds and methods for their formulation. Scope of the Patent The patent claims cover a broad range of anti-HBV agents, including specific peptide compounds, oligonucleotide compositions, and antibody constructs. These agents are designed to inhibit viral replication, attachment, and entry into host cells. The patent also encompasses various formulations for these anti-HBV agents, including pharmaceutical compositions and formulations for topical and systemic administration. Key Claims The patent lists several key claims, including: A method of treating or preventing HBV infection using a specific peptide compound or oligonucleotide composition. A pharmaceutical composition comprising a peptide compound or oligonucleotide composition and a pharmaceutical carrier. A method of inhibiting HBV replication using an antibody construct. Mechanisms of Action The patent describes various mechanisms by which the claimed anti-HBV agents act, including: Inhibition of HBV attachment to host cells. Prevention of HBV entry into host cells. Interference with HBV replication. Comparison to Prior Art The patent cites several prior art references, including existing anti-HBV agents and formulations. The patent claims to improve upon these references by providing novel compounds and methods of formulation that offer improved efficacy, reduced toxicity, and enhanced patient compliance. Relevance to Modern Research The patent's focus on developing novel anti-HBV agents and formulations remains relevant today. HBV remains a significant global health concern, and the need for effective treatments continues to drive research in the field. The patent's claims and description of mechanisms of action provide valuable insights for researchers seeking to develop new anti-HBV therapies. The patent has 43 total claims, including 22 dependent claims and 21 independent claims. The independent claims provide a broad scope for potential applications, while the dependent claims offer specific examples for practicing the invention. Global Impact The patent's global impact is significant, as it contributes to the growing body of knowledge on HBV treatment and prevention. As research continues to advance, it is likely that the patent's claims will influence the development of new anti-HBV therapies. This patent analysis provides an overview of the scope and claims of US Patent 7837235. The patent's focus on novel anti-HBV agents and formulations remains relevant in today's research landscape, and its claims provide valuable insights for scientists seeking to develop new treatments for HBV.

Drugs Protected by US Patent 7,837,235

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes	7,837,235		Y
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	7,837,235		Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015		RX	Yes	Yes	7,837,235*PED				Y

Foreign Priority and PCT Information for Patent: 7,837,235

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2004 001 451	Jan 08, 2004
Germany	10 2004 001 451	Jan 8, 2004

International Family Members for US Patent 7,837,235

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E380595
Australia	2004311644
Brazil	PI0418364